- Home
- RPAY vs RLMD Comparison
RPAY vs RLMD Comparison
Compare RPAY & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | RLMD |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 319.7M |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RPAY | RLMD |
|---|---|---|
| Price | $3.05 | $6.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $6.81 | ★ $10.25 |
| AVG Volume (30 Days) | ★ 1.3M | 542.6K |
| Earning Date | 06-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $309,261,000.00 | $13,070.00 |
| Revenue This Year | $0.22 | N/A |
| Revenue Next Year | $7.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $2.70 | $0.24 |
| 52 Week High | $5.98 | $5.12 |
Technical Indicators
Market Signals| Indicator | RPAY | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 69.19 |
| Support Level | $2.98 | $3.65 |
| Resistance Level | $3.87 | N/A |
| Average True Range (ATR) | 0.20 | 0.47 |
| MACD | 0.02 | 0.25 |
| Stochastic Oscillator | 56.78 | 76.45 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.